showed that their ROR1-targeting CAR T-cells induced TGF-β expression in tumor cells that did not initially overexpress this cytokine, but that this was mitigated by dnTGF-βRII armoring, which restored anti-tumor activity (83). The gene discussed is ROR1; the disease is neoplasm.